Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Preliminary Efficacy of YK-029A, a Novel EGFR TKI, in Patients With Advanced NSCLC Harboring ex20ins, T790M or Rare Mutations

NCT05767866 is registered in ClinicalTrials.gov with Suzhou Puhe Pharmaceutical Technology Co., LTD as lead sponsor.

NCT NCT05767866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Preliminary Efficacy of YK-029A, a Novel EGFR TKI, in Patients With Advanced NSCLC Harboring ex20ins, T790M or Rare Mutations
Lead sponsor
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 30, 2018
Completion date
May 30, 2024
Enrollment
160 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

treatment, treatment side effects